Last $2.37 USD
Change Today -0.13 / -5.20%
Volume 50.0K
VRML On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 5:20 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Snapshot

Open
$2.50
Previous Close
$2.50
Day High
$2.51
Day Low
$2.30
52 Week High
03/4/14 - $3.83
52 Week Low
12/13/13 - $1.97
Market Cap
84.9M
Average Volume 10 Days
21.0K
EPS TTM
$-0.39
Shares Outstanding
35.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERMILLION INC (VRML)

Related News

No related news articles were found.

vermillion inc (VRML) Related Businessweek News

No Related Businessweek News Found

vermillion inc (VRML) Details

Vermillion, Inc., together with its subsidiaries, is engaged in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. It develops diagnostic tests in the fields of oncology and women’s health. The company’s lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was founded in 1993 and is headquartered in Austin, Texas.

26 Employees
Last Reported Date: 03/31/14
Founded in 1993

vermillion inc (VRML) Top Compensated Officers

Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $184.0K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

vermillion inc (VRML) Key Developments

Vermillion, Inc. Appoints Judith K. Wolf as Chief Medical Officer, Effective September 15, 2014

Vermillion, Inc. appointed Dr. Judith K. Wolf to the new position of chief medical officer, effective September 15, 2014. Dr. Wolf is a highly accomplished, widely published and active professional in the field of gynecologic cancer. Over the last eight years, she has held numerous academic and administrative positions at the University of Texas and Banner MD Anderson Cancer Centers, and currently serves as the division chief of Surgical Oncology and vice chair of the Department of Oncology Services at the Banner MD Anderson Cancer Center in Arizona. Dr. Wolf is also presently an adjunct professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center, and a clinical professor of Division of Clinical Education at Arizona College of Osteopathic Medicine.

Vermillion, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Cash Flow Guidance for the Second Quarter of 2014

Vermillion, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the period, the company reported total revenue of $305,000 against $328,000 a year ago. Loss from operations was $3,995,000 against $2,602,000 a year ago. Loss before income taxes was $3,987,000 against $2,571,000 a year ago. Net loss was $3,987,000 against $2,571,000 a year ago. Basic and diluted net loss per share was $0.11 against $0.17 a year ago. The company used $3.5 million in cash for operations in the first quarter of 2014. For the second quarter of 2014, the company expects cash used in operations to be between $3.3 million to $3.8 million.

Vermillion, Inc. to Report Q1, 2014 Results on May 15, 2014

Vermillion, Inc. announced that they will report Q1, 2014 results at 9:01 PM, GMT Standard Time on May 15, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $2.37 USD -0.13

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.14 USD -0.004
Health Discovery Corp $0.03 USD -0.001
Imperial Innovations Group PLC 460.00 GBp +8.50
MDxHealth €3.47 EUR +0.043
Miraculins Inc C$0.16 CAD 0.00
View Industry Companies
 

Industry Analysis

VRML

Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.9x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit www.vermillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.